FDA Approves Trelegy Ellipta for COPD - Medscape
Sep 19, 2017 · The FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline) for patients with COPD.
FDA Expands Indication for Trelegy Ellipta in COPD - Medscape
Apr 24, 2018 · The FDA first approved Trelegy Ellipta in September 2017 for the long-term, once-daily maintenance treatment of COPD patients who are receiving Breo Ellipta (fluticasone …
EU Approves Trelegy Ellipta for COPD - Medscape
Nov 16, 2017 · The European Commission has granted marketing authorization for fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline PLC and Innoviva, Inc ...
FDA Approves Umeclidinium and Vilanterol Combo for COPD
Dec 18, 2013 · The FDA has approved umeclidinium and vilanterol powder for inhalation for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease.
Combo COPD Drug Umeclidinium/Vilanterol Cleared in Europe
May 8, 2014 · The European Commission has approved the combination of umeclidinium and vilanterol (Anoro) dry powder inhalation for once-daily maintenance treatment of COPD in adults.
FDA OKs Umeclidinium (Incruse Ellipta) for COPD - Medscape
Apr 30, 2014 · The once-daily anticholinergic is approved for maintenance treatment of airflow obstruction in patients with COPD.
Canada Clears Umeclidinium (Incruse) for COPD - Medscape
Apr 18, 2014 · The long-acting muscarinic antagonist is indicated for long-term maintenance bronchodilator treatment of airflow obstruction in adults with COPD.
Combination Inhalers for COPD: What Are the Benefits? - Medscape
Oct 22, 2015 · Finally, long-acting bronchodilator combinations are available for COPD management. Nicholas Gross reviews the efficacy and benefits of these therapies as determined in two recent trials.
Umeclidinium (Incruse) for COPD Approved in Europe - Medscape
Apr 28, 2014 · The long-acting muscarinic antagonist is indicated for long-term maintenance bronchodilator treatment of airflow obstruction in adults with COPD.
EU Panel Backs Umeclidinium (Incruse) for COPD - Medscape
Feb 20, 2014 · The committee favored approval of the long-acting muscarinic antagonist umeclidinium for once-daily maintenance treatment of chronic obstructive pulmonary disease in adults.